Evolus, which is preparing to launch a biosimilar version of Botox, announced terms for its IPO on Monday.
The Irvine, CA-based company plans to raise $65 million by offering 5 million shares at a price range of $12 to $14. At the midpoint of the proposed range, Evolus would command a fully diluted market value of $313 million.
Evolus was founded in 2012 and plans to list on the Nasdaq under the symbol EOLS. Cantor Fitzgerald and Mizuho Securities are the joint bookrunners on the deal.
